KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $255.2 million.

  • Nektar Therapeutics' Cash & Current Investments rose 10.52% to $270.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.0 million, marking a year-over-year decrease of 17.01%. This contributed to the annual value of $255.2 million for FY2024, which is 15.94% down from last year.
  • As of FY2024, Nektar Therapeutics' Cash & Current Investments stood at $255.2 million, which was down 15.94% from $303.6 million recorded in FY2023.
  • Nektar Therapeutics' Cash & Current Investments' 5-year high stood at $1.1 billion during FY2020, with a 5-year trough of $255.2 million in FY2024.
  • For the 3-year period, Nektar Therapeutics' Cash & Current Investments averaged around $354.6 million, with its median value being $303.6 million (2023).
  • Data for Nektar Therapeutics' Cash & Current Investments shows a maximum YoY slumped of 39.88% (in 2023) over the last 5 years.
  • Nektar Therapeutics' Cash & Current Investments (Yearly) stood at $1.1 billion in 2020, then slumped by 30.88% to $734.0 million in 2021, then crashed by 31.20% to $505.0 million in 2022, then tumbled by 39.88% to $303.6 million in 2023, then dropped by 15.94% to $255.2 million in 2024.